EHA 2017 | Present issues in treating patients with relapsed/refractory CLL
Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from St James’s University Hospital Leeds, Leeds, UK, talks to us about managing the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and the clinical issues observed in patients failing treatment with B-cell receptor inhibitors. Here at EHA 2017, Prof. Hillmen and his team presented a number of cases on how physicians could manage the toxicities and progressions in CLL patients treated with novel therapies. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
Get great new content delivered to your inboxSign up